Biobanking Market - Global Forecast 2025-2032

The biobanking market continues to transform as organizations adapt to new demands in biological sample management and enable critical advancements in clinical research, medical innovation, and personalized healthcare. Staying ahead in this space demands strategic modernization and operational agility from senior decision-makers.

Market Snapshot: Biobanking Market Size and Growth

The global biobanking market grew from USD 72.98 billion in 2024 to USD 81.37 billion in 2025. Projections estimate a compound annual growth rate (CAGR) of 12.10%, with the market expected to reach USD 182.03 billion by 2032. This sustained expansion reflects increasing demand for reliable sample preservation, advanced data integration, and seamless multinational collaboration. Growth also highlights mounting opportunities and competitive pressures for organizations operating at every stage of the biobanking value chain.

Scope & Segmentation of the Biobanking Market

This comprehensive report analyzes the biobanking industry across core offerings, technology frameworks, and global regions, providing actionable intelligence for strategic planning:

• Offering: Automated storage systems, cryogenic equipment, laboratory freezers and incubators, consumables, and sample transport solutions. Services include compliance support, advanced sample logistics, robust data management, and specialized software platforms for end-to-end biobank operations.
• Biobank Type: Traditional physical biobanks and virtual platforms, supporting a range of storage strategies and data accessibility models tailored to both established and emerging research needs.
• Sample Type: Blood products, cellular materials, nucleic acid samples, and tissue specimens, each playing a vital role in research pipelines and influencing biobank workflows and facility requirements.
• Application: Integration into diagnostic and therapeutic development, as well as drug discovery and broader clinical research, demonstrating the diverse utility of biobanks across healthcare and life sciences.
• End User: Academic research centers, contract research organizations, public health agencies, hospitals, clinical laboratories, pharmaceutical firms, and biotechnology companies, all driving sector demand.
• Geographical Coverage: Major markets across the Americas (spanning North and Latin America), Europe, Middle East and Africa, and Asia-Pacific. Countries such as China, India, Japan, and Australia represent focal points for industry growth and innovation.

In addition, the report examines strategic activities and technology adoption by leading global organizations, including Thermo Fisher Scientific Inc., Avantor, Inc., and Azenta Life Sciences—offering clear insights into evolving market dynamics, partnerships, and competitive positioning.

Key Takeaways for Senior Biobanking Stakeholders

• Adoption of cloud-based infrastructure, advanced analytics, and artificial intelligence enhances end-to-end sample traceability, enables predictive equipment maintenance, and supports continuous operational improvement for facilities of all sizes.
• Sustainability targets drive new investments in low-energy cold storage and eco-friendly preservation practices, aligning with international climate objectives and reducing environmental impact.
• Collaboration via global consortia and adherence to standardized processes fosters sample consistency, improves data interoperability, and broadens the reach of multicenter research initiatives.
• Changing regulatory frameworks increase the need for adaptive compliance strategies, stronger data governance, and innovative consent management throughout the biobanking ecosystem.
• Growing complexity within the sector elevates the importance of specialized workforce skills, improved training, and ongoing professional development to maintain standards in quality and compliance.

Tariff Impact: Addressing Supply Chain and Cost Challenges

Recent changes to United States tariffs in 2025 have introduced significant procurement pressures for key laboratory reagents, consumables, and equipment. Organizations contend with longer lead times and supply chain disruptions, leading to strategic shifts such as diversifying suppliers, relocating production closer to end-users, and collaborating with regulators to secure sector-specific exemptions. These trends directly affect project planning, budget management, and partnership alignment, making flexible sourcing and risk mitigation central to resilient biobanking operations.

Methodology & Data Sources

This report is informed by primary interviews with industry leaders and is supported by extensive secondary research from regulatory submissions, peer-reviewed publications, and market trend databases. All quantitative data have been cross-verified through rigorous statistical analysis to ensure accuracy and reliability.

Why This Report Matters for Senior Decision-Makers

• Enables informed procurement and operational strategy by highlighting crucial market segments, technology shifts, and contemporary supply chain realities in the biobanking sector.
• Delivers up-to-date analysis of emerging sector risks, regulatory priorities, and sustainability strategies, fundamental for navigating complex compliance and partnership environments.

Conclusion

Biobanking leaders are positioned to drive future growth by investing in advanced technology, building adaptable supply networks, and nurturing skilled teams. This research provides the clarity necessary to steer organizations confidently through evolving industry challenges.